ISFA 2025 SCIENTIFIC PROGRAM

Time	Mayfair A-B	Mayfair C
	Thursday, July 1	.7
07:00 - 08:00	Registration	
08:00 - 09:30	Apheresis around the world 1: joint workshop with JSFA	Apheresis in sepsis and ARDS: mechanisms, therapies, and clinical applications
	Chair: Ken Yamaji (Japan)	Chair: Tadao Akizawa (Japan)
	Chair: (Thailand)	Chair: (Thailand)
	Keynote address "Current status of therapeutic apheresis in Japan 1" (5 min) Ken Yamaji (Japan)	Apheresis treatment in critical care setting Jan Kielstein (Germany)
	Efficacy of plasma exchange for rapidly progressive interstitial lung disease (RP-ILD) in anti-MDA5-positive dermatomyositis (DM) (20+7 min)	Extracorporeal blood purification for sepsis; emerging role of apheresis?
	Makio Kusaoi (Japan)	Rasheed Abiodun Balogun (USA)
	Granulocyte monocyte apheresis (GMA) for ulcerative colitis (UC) (20+7 min) Yoko Yokoyama (Japan)	Extracorporeal blood purification for sepsis : role of adsorptive therapy Ranistha Ratanarat (Thailand)
	Evolving treatment strategies for patients with chronic limb-threatening ischemia in Japan-viscosity intervention with Rheocarna therapy after revascularization (20+7 min)	
	Keisuke Miyake (Japan)	
09:30 - 10:30		and plenary lecture
		lenges for apheresis in Thailand
		amaji (Japan)
	Speaker: Kriengsak Va	reesangthip (Thailand)
10:30 - 11:00	Coffee Break ar	nd Poster Visiting
11:00 - 12:30	Apheresis around the world 2: joint workshop with JSFA	Extracorporeal Therapies in Liver Failure and Critical Illness: Innovations in CRRT, Plasma Exchange, and Adsorptive Techniques
	Chair: Ken Yamaji (Japan)	Chair: Wladimir Szpirt (Denmark)
	Chair: (Thailand)	Chair: (Thailand)
	Keynote address "Current status of therapeutic apheresis in Japan 2" (5 min)	Role of CRRT in liver failure (15+5)
	Ken Yamaji (Japan)	Thummaporn Naorungroj (Thailand)
	Apheresis therapy in secondary nephritic syndrome and/or diabetic kidney disease (20+7 min)	Total plasma exchange: a therapeutic approach (15+5)
	Kengo Furuichi (Japan)	Pitpibul Diewtrakulchai (Thailand)
	Apheresis therapy in the treatment strategy of neuromyelitis optica spectrum disorder (NMOSD) (20+7 min)	Adsorptive therapies: innovations and applications (15+5)
	Youwei Lin (Japan) Therapeutic apheresis for respiratory infections associated with COVID-19 infection (20+7 min)	Nuttha Lumlertgul (Thailand)
42.20 42.20	Daisuke Katagiri (Japan)	Look Consist on
12:30 - 13:30	Lunch Symposium Fresinius Kabi	Lunch Symposium Lipoprotein apheresis in cardiovascular disease: evolving strategies in FH and peripheral arterial disease
		Chair: Luigi Vernaglione (Italy)
		Chair: (Thailand)
		The current status of lipoprotein apheresis in familial hypercholesterolemia (FH) treatment with the use of molecular targeted drugs Mariko Harada-Shiba
		Apheresis with lipid and fibrinogen in peripheral arterial disease
12.22 15.22		Dusit Lumlertgul (Thailand)
13:30 - 15:00	Apheresis around the world 3: joint workshop with E-ISFA "Lipidology"	Evolving role of apheresis in autoimmune kidney diseases (17+5)
	Chair: Bernd Hohenstein (Germany)	Chair: Makio Kusaoi (Japan)
	Chair: (Thailand) Is lipoprotein apheresis effective for coronary microvascular dysfunction in CHD patients?	Chair: (Thailand) Apheresis in action: breaking barriers in autoimmune kidney disease treatment
	Alfonso Ramunni (Italy)	Wanjak Pongsittisak (Thailand)
	Apheresis treatment to improve rheology and microcirculation – indications and results	Apheresis in severe lupus nephritis
	Luigi Vernaglione (Italy) Will new lipid-lowering drugs make lipoprotein apheresis obsolete in the near	Ratana Chawanasuntorapoj (Thailand) Antinephrin-associated primary FSGS successfully treated with plasmapheresis - A
	future? Wolfgang Ramlow (Germany)	case report lain Bressendorff, Karl Emil Nelveg-Kristensen, Maryam Ghasemi, Andrew J.B.
		Watts, Johanna Elversang, Keith H. Keller, Finn Cilius Nielsen, <u>Wladimir Szpirt</u> , Astrid Weins
15:00 - 15:30 15:30 - 17:00	Coffee Break ar Apheresis around the world 4: joint workshop with E-ISFA "Autoimmunity"	nd Poster Visiting Role of lipoprotein apheresis in managing severe lipid disorders and cardiovascula diseases
	Chair: Wolfgang Ramlow (Germany)	Chair: Mariko Harada-Shiba (Japan)
	Chair: (Thailand)	Chair: (Thailand)
	Immunoadsorption – techniques and indications from a European perspective	Apheresis in patients with homozygous familial hypercholesterolemia (HoFH) – Indian experience
	Bernd Hohenstein (Germany) Immunoadsorption in steroid-refractory multiple sclerosis (MS)	Shamanna S. Iyengar (India) Lipoprotein apheresis: utility, outcomes and implementation in clinical practice
	[al	from a US perspective
	Johannes Dorst (Germany) The role of immunoadsorption in chronic inflammatory demyelinating polyneuropathy (CIDP)	Paul Barton Duell (USA)

Time	Room 1	Room 2
	Friday, July 18	
07:30 - 08:30	Morning Symposium	Morning Symposium
	Terumo BCT: Similar but not the same – Dawn of A New Age for Centrifugal	JIMRO: Apheresis treatment for reshaping immunological balance in Inflammatory
	Therapeutic Plasma Exchange (cTPE)	Bowel Disease (IBD)
08:30 - 10:00	and sustainability	Advancing Therapeutic Apheresis: Perspectives, Challenges, and Innovations
	Chair: Jan Kielstein (Germany)	Chair: Nicole A. Aqui (USA)
	Chair: (Thailand)	Chair: (Thailand)
	It's not the citrate! Impact of plasma exchange on calcium, phosphorus, vitamin D	Therapeutic apheresis in autoimmune disorders: Indian perspectives (15+5)
	and parathyroid hormone	Chiramana Chandrashalian (India)
	Amber P Sanchez (USA) Insights into apheresis procedures in Thailand, the national cohort	Shivaram Chandrashekar (India) Plasma exchange in TTP: mechanisms, benefits and challenges (15+5)
	Kornchanok Vareesangthip (Thailand)	Janejira Kittivorapart (Thailand)
	Green apheresis: sustainable solutions for an eco-friendly future in blood therapy	Apheresis adverse events of therapeutic and donor settings in Thailand (15+5)
	, , , , , , , , , , , , , , , , , , , ,	
	Tushar Chopra (USA)	Phandee Watanaboonyongcharoen (Thailand)
10:00 - 10:30	Coffee Break an	nd Poster Visiting
10:30 - 12:00	Apheresis around the world 5:	Therapeutic apheresis in neurology (17+5)
	joint workshop with ASFA "Evidence based guidelines for the use of therapeutic apheresis medicine in solid organ transplantation, precision therapeirs for cancer, general nephrology and	
	beyond." Chair: Chisa Yamada (USA)	Chair: Hidanari Mataua (Janan)
	Chair: Chisa Yamada (USA) Chair: Amber P Sanchez (USA)	Chair: Hidenori Matsuo (Japan) Chair: (Thailand)
	Evidence and decision making in apheresis medicine; the "ASFA Guidelines" 1986	Therapeutic Apheresis in Neurology: Historical Breakthroughs, Current Evidence,
	to 2026 and beyond	and Future Frontiers
	Laura Connelly-Smith (USA)	Saharat Aungsumart (Thailand)
	Apheresis medicine; first step in precision immunotherapy for cancer; the "designer medicines" (Chimeric Antigen Receptor T Cells)	Evidence base of TPE in seronegative immune mediated disease. Do we need antibody for guiding of TPE?
	Nicole A. Aqui (USA)	Metha Apiwattanakul (Thailand)
	Immune modulation with extracorporeal phototherapy; clinical successes	Apheresis therapy in the treatment strategy of autoimmune encephalitis (AE)
	Jennifer Schneiderman (USA)	Satoru Oji (Japan)
		Mechanism of Action of Blood Purification Discovered in Multiple Sclerosis (MS) Research
		Youwei Lin (Japan)
12:00 - 13:00	Lunch Symposium	Lunch Symposium
	AsahiKASEI: Apheresis for Tomorrow: Advancing Global Collaboration from Japan	Kaneka
	and Thailand	
13:00 - 14:30	Apheresis around the world 6:	Lipoprotein(a) [Lp(a)] in cardiovascular disease, bridging the gap between
	joint workshop with SEATPEC	pathophysiology, emerging science, and clinical practice
	Chair: Shanthi Viswanathan (Malaysia)	Chair: Patrick Moriarty (USA)
	Chair: Sasitorn Siritho (Thailand)	Chair: (Thailand)
	Semi-critical use of TPE within the SEATPEC region and its challenges : case based	Lipoprotein-apheresis improves HDL proteomics and reduces the risk of aortic valve stenosis in patients with elevated Lp(a) levels
	Jiraporn Jitprapaikulsan (Thailand)	Patrick Moriarty (USA)
	TPE selection and outcome measurements within SEA: practice variabilities	Lipoprotein(a) – unraveling its multifaceted role in cardiovascular pathophysiology
	Hiew Fu Liong (Malaysia)	Jeffrey Kroon (Netherlands)
	Feasibility of small volume plasma exchange: the Myanmmar experience	Lipoprotein(a) – when science meets clinical routine
	Ohnmar Ohnmar (Myanmar)	Wolfgang Ramlow (Germany)
14:30 - 15:00		d Poster Visiting
15:00 - 16:30	Innovative and comparative aspects of apheresis	Vascular access strategies for apheresis medicine
	Chair: Shamanna S. Iyengar (India)	Chair: Laura Connelly-Smith (USA) Chair: (Thailand)
	Chair: (Thailand) Comparison of plasma exchange techniques – centrifugation versus filtration	Vascular access for extracorporeal treatment – developments from a Chinese
	Jan Kielstein (Germany)	perspective (20+5) Deling Kong (China)
	Veterinary use of sorbent technology for clinical apheresis	Pediatric vascular access (20+5)
	Larry D. Cowgill (USA)	Hyogo Nakakura (Japan)
	Randomized placebo (sham pheresis) controlled trial evaluating therapeutic plasma	Special aspects of vascular access for apheresis in Thailand (20+5)
	exchange for the mitigation of the effects of aging in humans Dobri Kiprov (USA)	Sukit Ruksasuk (Thailand)
Time	Room 1	Room 2
	Saturday, July 1	
07:30 - 08:30	Morning Symposium	Morning Symposium
	Innovative Therapies in Fluid and Electrolyte Disorders: Rhabdomyolysis and	Nursing care
	Ascites Management Chair: Rasheed Abiodun Balogun (USA)	Chair: Nicole A. Aqui (USA)
	Chair: (Thailand)	Chair: (Thailand)
	Hemoadsorption for myoglobin removal in rhabdomyolysis: When and how to do it	
	Jan Kielstein	
	Cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites	Betty Doggett (USA) The nurse's role in therapeutic apheresis
		·
00.00 15.55	Yuji Kamijo (Japan)	Nuntana Spilles (Thailand)
08:30 - 10:00	Role of apheresis in nephrotic syndrome and preeclampsia 17+5	Oral abstract presentation 10+5
	Chair: Takafumi Ito (Japan) Chair: (Thailand)	Chair: Mariko Seishima (Japan) Chair: Hiew Fu Liong (Malaysia)
	Japanese indication and clinical efficacy of low-density lipoprotein apheresis for	Chair. Thew I a Living (ividiaysia)
	refractory nephrotic syndrome	
	Eri Muso (Japan) Possible mechanisms of the beneficial effect of apheresis therapy on primary	
	nephrotic syndrome	

	181 - 18 AP - et al II - e al A		
	Hitomi Miyata (Japan)		
	Japanese indication and clinical efficacy of low-density lipoprotein apheresis for		
	chronic limb-threatening ischemia		
	Hitoshi Suzuki (Japan)		
	A feasibility study to evaluate safety of the KNP-1000 Apheresis System in patients		
	with preeclampsia with severe features		
	Marc Parrish (USA)		
10:00 - 10:30		nd Poster Visiting	
10:30 - 12:00	The use of apheresis in kidney transplantation	Cell collections – principles, techniques, and Quality	
	Chair: Lionel Rostaing (France)	Chair: Joseph Schwartz (USA)	
	Chair: (Thailand)	Chair: (Thailand)	
	Solid organ transplantation; value added apheresis, or not? The kidneys (20+5min)	HPC collections for transplantation – Basic concepts & techniques	
	Chisa Yamada (USA)	Nicole A. Aqui (USA)	
	Optimizing transplantation: apheresis and antibody removal techniques (15+5min)	HPC collection efficiency – what & how to improve	
	Nutavudh Townamchai (Thailand)	Laura Connelly-Smith (USA)	
	Complications during apheresis for kidney transplant indications (15+5min)	Quality – standards to improve cell collections	
	Chimezie Godswill Okwuonu (Nigeria)	Joseph Schwartz (USA)	
	Advancements in high immunologic kidney transplantation: optimizing outcomes with innovative plasmapheresis and hemodialysis strategies (15+5min)		
	Surasak Kantachuvesiri (Thailand)		
12:00 - 13:00	Lunch Symposium	Lunch Symposium	
	Apheresis in Solid Organ Transplantation: Optimizing Outcomes in Lung and Kidney Transplants	Apheresis in nephrology	
	Chair: Takuya Ueno (USA)	Chair: Luigi Vernaglione (Italy)	
	Chair: (Thailand)	Chair: (Thailand)	
	Solid organ transplantation; value added apheresis, or not? The lungs	Selective and semi-selective apheresis: How and why?	
	Max M. Weder (USA)	Olivier Moranne (France)	
	Apheresis to desentize ABO incompatible kidney transplant candidates with	Lipoprotein apheresis in FSGS	
	extremely high isoagglutinin titers	z.pop.otem opnerosis in 1965	
	Lionel Rostaing (France)	Joshua J. Zaritsky (USA)	
13.00 - 14.30	Management of plasmapheresis in neonates and infants	Apheresis in ANCA-associated vasculitis	
15.00 14.50	Chair: Larry Cowgill (USA)	Chair: Wladimir Szpirt (Denmark)	
	Chair: Konggrapun Srisuwan (Thailand)	Chair: (Thailand)	
	Management of plasmapheresis in neonates and infants (15+5)	Does plasma exchange have a role in ANCA-associated vasculitis?	
	Wanagement of plasmapheresis in neonates and imanes (1515)	Yes, under some circumstances.	
	Mariko Sawada (Japan)	Wladimir M Szpirt, Balazs Odler, Andreas Kronbichler	
	Plasmapheresis in pediatric vasculitis and autoimmune diseases (15+5)	The effect of plasma exchange on early renal response among patients with ANCA-	
	0:: - 0: ::/\tau !! !!	associated glomerulonephritis	
	Sirirat Charunanij (Thailand)	Balazs Odler, Regina Riedl, Duvuru Geetha, Wladimir M. Szpirt, Carmel Hawley, Lisa Uchida, Zachary S. Wallace, Giles Walters, Eri Muso, Vladimir Tesar, Charles D. Pu- sey, Mark A. Little, Peter A. Merkel, Michael Walsh, David R.W. Jayne, Andreas Kronbichler, for the PEXIVAS investigators	
	Plasmapheresis in children: an overview of technical aspects and experience in pediatric kidney disease (15+5)	The impact of kidney relapse on long-term kidney function in ANCA-associated vasculitis	
	Konggrapun Srisuwan (Thailand)	Lisa Uchida, Vanja Ivkovic, Anna Matyjek, Duvuru Geetha, Balazs Odler, Carmel Haw-ley, Zachary S. Wallace, Carol McAlear, Mats Junek, Peter A. Merkel, Michael Walsh, David R.W. Jayne, Andreas Kronbichler, on behalf of the PEXIVAS investigators	
14:30 - 15:00	Coffee Break and Poster Visiting		
15:00 - 16:00	Closing ceremony and Awards		
	Joseph Schwartz (WAA president) future of apheresis WAA perspective		
	Ken Yamaji (ISFA outgoing president) Rasheed Balogun (ISFA incoming president) future of apheresis ISFA perspective		
	Kriengsak Vareesangti	nip (congress president)	